Novartis Hematology: Relentless Pursuit of a Cure

Scientist in lab

Novartis is deeply committed to transforming the lives of people living with blood cancers and life-threatening blood disorders. We believe that anyone living with these conditions has the right to a life free from pain, free from symptoms, and free from disease – this is our vision for the future.

Reimagining Myeloid Disorders

Novartis – together …

/by

Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program

  • Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase1
  • In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and retinal vascular occlusion versus aflibercept1
  • Patient safety is of paramount …
/by

Two Decades of Pioneering Innovation in CML and Beyond

Scientist checking samples

A Breakthrough for CML and Cancer Treatment

In May 2001 – exactly 20 years ago – Novartis received approval from the US Food and Drug Administration (FDA) for the first targeted therapy for cancer, known as a tyrosine kinase inhibitor (TKI). This was a watershed moment in drug discovery, transforming the treatment landscape for chronic …

/by